Years ago the number one reason to try something new in diabetes was to benefit the patient. This is what led to new insulins, oral medications and devices like insulin pumps and continuous glucose monitors. All was going well till the PBM’s got involved. Now it all about what is …

Antioxidants and other polyphenols present in coffee confer healthy benefits to the body, which may include lowering insulin resistance, inflammation and biomarkers of liver function.

The treatment of choice for obese T2D patients is weight loss.

Earlier initiation of diabetes medications can lead to reduced heart disease risk in type 2 patients.

Management of non-glycemic cardiovascular disease risk factors may have increasing benefits in an aging type 1 diabetes patient population with long-term hyperglycemia.

Guest Post by David Kliff, Diabetic Investor. New diabetes technology sounds promising, but will products like One Drop really change patients' -- or payers' -- behavior?

Which of the following are strict or relative contraindications to the use of some of the GLP-1 agonists? A. Multiple endocrine neoplasia (MEN) syndrome type 2 B. Personal or family history of medullar thyroid cancer C. Pancreatitis D. All of the above Follow the link to see the right answer.

Do you think that a single-payer heathcare system would help to provide better care at less cost? Follow the link to share your opinion.

Diabetes in Control speaks with Dr. Stuart Weiss about his private practice experiences and his typical patient recommendations, including how to determine the best possible diabetes drug treatment, embracing CGM systems, and CGM reimbursement.

In this Exclusive Interview, Dr. Stuart Weiss talks with Diabetes in Control Publisher Steve Freed during the AACE meeting in Austin, Texas about his experiences in private practice in New York.